Skip to main content

Skyward Specialty Insurance Group, Inc.

For the period ended Mar 31, 2025. Filed May 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

SKWD$59.80-0.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 5. Other Information

During the quarter ended March 31, 2025, certain of our executives entered into or amended existing written plans during an open insider trading window for the purchase or sale of our securities that are intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies regarding transactions in our securities.

On March 6, 2025, Andrew Robinson, Chief Executive Officer, modified his Rule 10b5-1 Trading Arrangement, originally adopted on September 10, 2024, to change the start date of the second tranche from May 9, 2025 to June 6, 2025. The modified plan provides for the sale of up to an aggregate of 36,271 shares of our common stock that remain available for sell.

On March 12, 2025, Mark Haushill entered into a new Rule 10b5-1 Trading Arrangement. The material terms of these trading plans are set forth in the table below.

Disclosure EventsName (Title)Date of AdoptionNature of Trading ArrangementDuration of Trading ArrangementAggregate Number of Securities
1Andrew Robinson (Chief Executive Officer)September 10, 2024; Amended second order of plan on March 6, 2025Rule 10b5-1(c) Trading Arrangement1/2/2025 – 6/30/2025Up to 60,358 shares
2Mark Haushill (Chief Financial Officer)March 12, 2025Rule 10b5-1(c) Trading Arrangement6/13/2025 – 3/31/2026Up to 75,000 shares
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.